{
  "id": "5a7610af83b0d9ea6600001a",
  "type": "factoid",
  "question": "Which Janus kinase does decernotinib target?",
  "ideal_answer": "Decernotinib (VX-509) is a potent and selective inhibitor of janus kinase 3 (JAK3).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25762693"
  ],
  "snippets": [
    {
      "text": "The aim of this study was to evaluate the potency and selectivity of the investigational JAK3 inhibitor VX-509 (decernotinib) [(R)-2-((2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide]against JAK3 kinase activity and inhibition of JAK3-mediated signaling in vitro and JAK3-dependent physiologic processes in vivo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25762693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results demonstrate that VX-509 potently inhibits JAK3 in enzyme assays (Ki = 2.5 nM + 0.7 nM) and cellular assays dependent on JAK3 activity (IC50 range, 50-170 nM), with limited or no measurable potency against other JAK isotypes or non-JAK kinases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25762693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These findings demonstrate that VX-509 is a selective and potent inhibitor of JAK3 in vitro and modulates proinflammatory response in models of immune-mediated diseases, such as collagen-induced arthritis and delayed-type hypersensitivity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25762693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25762693",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Janus kinase 3 (JAK3)"
}